Agenda

*Schedule is tentative and is subject to change.

Cellular Therapies and Novel Blood Products in Trauma and Critical Care – The Future of Transfusion Medicine

Wednesday, December 11 | Barriers in Translation for Novel Products in Trauma and Critical Care

Discussion and talks will focus upon funding, translation, cell product production and processing

11:00 am - 5:00 pm
Registration Open – Aragon Pre-Function North

Badge and Materials Pickup

2:55 pm - 3:00 pm
Welcome & Introductions
  • Shibani Pati MD, PhD

    CTTACC Conference Chair
    Professor of Laboratory Medicine, UCSF
    Scientific Director of Cellular Therapies

3:00 pm - 3:45 pm
Session 1 | Sustainability of Research and Successful Translation of Novel Therapeutics in Trauma and Critical Care: from Bench to Bedside and Beyond

Discussion will focus upon funding support for the translational pipeline which includes the infrastructure needed for pre-clinical and clinical trials in trauma and critical care. Funding from federal sources, industry, philanthropy and venture capital will be discussed. Panelists will include representation from the NIH, BARDA, DOD, industry stakeholders and a venture capital firm.

  • Moderator: Raymond Goodrich PhD

    Executive Director, Infectious Disease Research Center
    Office of the Vice President for Research
    Professor, Department of Microbiology, Immunology and Pathology,
    Colorado State University

  • Geoffrey Ling MD, PhD

    Col, USAF, Ret.
    Chief Executive Officer at SunQ, LLC
    Ex Director of the Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office

  • Mary Homer PhD

    Chief United States Radiological and Nuclear Countermeasures, Division of Chemical, Biological, Radiological, and Nuclear Countermeasures
    Biomedical Advanced Research and Development Authority (BARDA)

  • Michael Davis MD, FACS

    Col, USAF
    Director of the US Army Medical Research and Materiel Command’s Combat Casualty Care Research Program (CCCRP)

3:44 pm - 5:20 pm
Session 2 | Challenges in Product Development, Cell Production and Processing

Discussion will focus upon the translational barriers and challenges that exist in cell product production, development and processing. Panelists will include representation from the private industry, blood banks, NIH and academic centers involved in this space.

3:45 pm - 4:05 pm
Challenges of Clinical Cell Product Production in an Academic Center: Manufacturing Autologous Regulatory T Cell Products
  • Jonathan Esensten MD, PhD

    Medical Director, UCSF HICTF and GMP Facility Medical Director,
    Zuckerberg San Francisco General Hospital Blood Bank and Transfusion
    Service Assistant Adjunct Professor, Dept. of Laboratory Medicine

4:05 pm - 4:25 pm
Analysis of Stem Cell Heterogeneity to Identify Potency Markers
  • Dave Stroncek MD

    Chief of Cell Processing
    National Institutes of Health

4:25 pm - 5:25 pm
Cell Production Panel
  • Moderator: Kenneth Bertram MD, PhD

    Co-Chair CTTACC
    COL, USA, Ret.
    Professor of Regenerative Medicine
    Wakeforest University

  • Becky Cap

    COO Gencure/BioBridge Global

  • Dave Stroncek MD

    Chief of Cell Processing
    National Institutes of Health

  • Fabio Triolo D.d.R., M.Phil., PhD

    Director, Cellular Therapy Core
    Associate Professor Program in Regenerative Medicine
    Department of Pediatric Surgery
    University of Texas Houston

  • Jon Rowley PhD

    Chief Executive & Technology Officer, RoosterBio, Inc.

  • Julie Allickson PhD

    Director, Regenerative Medicine Clinical Center
    Wake Forest University School of Medicine

  • Robert Mays PhD

    Vice President, Regenerative Medicine
    Head of Neurosciences, Athersys, Inc.

5:25 pm - 5:50 pm
Session 3 | Optimizing the Tail End of Cell Product Development and Delivery to Patients

Discussion will focus upon the current successes and challenges that exist in finalizing the end of product development which includes optimal cryopreservation, storage, shipping, handling and delivery of the final product to patients. These are areas that are critical for the success and safety of the products, clinical trials and final patient outcomes. Panelists will include representation from the private industry, blood banks and academic centers involved in this space.

  • Moderator: Aby J. Mathew PhD

    Senior VP & CTO
    BioLife Solutions

  • Moderator: Shibani Pati MD, PhD

    CTTACC Conference Chair
    Professor of Laboratory Medicine, UCSF
    Scientific Director of Cellular Therapies

  • Christopher Murphy

    M SGT, USA, Ret.
    CEO Combat Medical Solutions

  • David McKenna MD

    Professor of Transfusion Medicine
    Director of the Division of Transfusion Medicine
    University of Minnesota

  • Donna Chang PhD

    President & CEO
    Hope Biosciences

  • Fabio Triolo D.d.R., M.Phil., PhD

    Director, Cellular Therapy Core
    Associate Professor Program in Regenerative Medicine
    Department of Pediatric Surgery
    University of Texas Houston

6:00 pm - 7:00 pm
Reception – Aragon Terrace
7:00 pm - 7:30 pm
2019 Keynote | The Power of Yes
  • Geoffrey Ling MD, PhD

    Col, USAF, Ret.
    Chief Executive Officer at SunQ, LLC
    Ex Director of the Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office

7:30 pm - 9:00 pm
Dinner – Aragon Lawn

Thursday, December 12 | Transfusion Medicine in Trauma and Critical Care

The goal of this session is to discuss and understand pertinent issues in transfusion medicine and novel blood products related to the bleeding and acutely injured trauma patient. Topics of discussion will focus around novel blood products and adjuncts to resuscitation in bleeding patients.

7:00 am - 8:00 am
Breakfast | Aragon Lawn

Visit Exhibits

7:00 am - 5:00 pm
Registration Area Open – Aragon Pre-Function North

Badge and Materials Pickup

8:00 am - 8:05 am
Welcome & Introduction
  • Shibani Pati MD, PhD

    CTTACC Conference Chair
    Professor of Laboratory Medicine, UCSF
    Scientific Director of Cellular Therapies

Session 1 | Whole Blood – The First Cell Therapy in Trauma

8:05 am - 8:20 am
Civilian Whole Blood Use: The Portland, OR Experience
  • Martin Schreiber MD

    CTTACC Conference Co-Chair
    COL, USAR
    Professor of Surgery & Chief of Trauma, Critical Care & Acute Care Surgery
    Oregon Health & Science University (OHSU)

8:20 am - 8:35 am
Military Whole Blood Use
  • Stacey Shackleford MD

    Col, USAF
    Chief, Joint Trauma System Defense Center of Excellence for Trauma
    US Army Institute of Surgical Research

8:35 am - 8:50 am
Civilian Whole Blood Use: The Pittsburgh, PA Experience
  • Jason Sperry MD, MPH

    Professor of Surgery and Critical Care
    Director of Acute Care Surgery Fellowship
    University of Pittsburgh

8:50 am - 9:05 am
Question & Answer Panel | Session 1
  • Moderator: Paul Ness MD

    Senior Director, Division of Transfusion Medicine
    Professor of Pathology
    Johns Hopkins University

Session 2 | Novel Resuscitation Adjuncts and Blood Products in Trauma

9:05 am - 9:20 am
Resuscitation Adjuncts in Trauma
  • Hasan Alam MD

    Norman W. Thompson Professor of Surgery
    Section Head of General Surgery
    University of Michigan

9:20 am - 9:35 am
Prehospital Plasma First Resuscitation : Impact of Transport Time
  • Ernest Moore MD

    Professor of Surgery
    Vice Chair of Research
    Editor of Journal of Trauma and Acute Care Surgery

9:35 am - 9:50 am
Tranxanemic Acid as a Resuscitative Adjunct for Treatment of TBI
  • Martin Schreiber MD

    CTTACC Conference Co-Chair
    COL, USAR
    Professor of Surgery & Chief of Trauma, Critical Care & Acute Care Surgery
    Oregon Health & Science University (OHSU)

9:50 am - 10:05 am
Endothelial and Mitochondrial Effects of TXA
  • Joseph Rappold MD

    Co-Chair CTTACC
    CAPT, USN, Ret.
    Professor of Surgery
    Maine Medical Center Tufts University

10:05 am - 10:20 am
Precision Approaches to Trauma Resuscitation – Results of the ITACTIC Trial
  • Karim Brohi MD

    Professor of Trauma Sciences
    Queen Mary University of London
    Director London Major Trauma System

10:20 am - 11:05 am
Question & Answer Panel | Session 2

Discussion Panel on Challenges in the Development, Study and Implementation of Pre-hospital Interventions

  • Moderator: John Holcomb MD, FACS

    Co-Chair CTTACC
    COL, USA, Ret.
    Professor of Surgery
    University of Texas Houston

  • Beth Shaz MD

    President AABB
    Chief Medical and Scientific Officer
    Senior Vice President at New York Blood Center

  • Christophe Martinaud MD

    Professor of Transfusion Medicine and Cell Therapy
    French Military Blood Institute Clamart

  • Ernest Moore MD

    Professor of Surgery
    Vice Chair of Research
    Editor of Journal of Trauma and Acute Care Surgery

  • Jason Sperry MD, MPH

    Professor of Surgery and Critical Care
    Director of Acute Care Surgery Fellowship
    University of Pittsburgh

  • Karim Brohi MD

    Professor of Trauma Sciences
    Queen Mary University of London
    Director London Major Trauma System

  • Martin Schreiber MD

    CTTACC Conference Co-Chair
    COL, USAR
    Professor of Surgery & Chief of Trauma, Critical Care & Acute Care Surgery
    Oregon Health & Science University (OHSU)

  • Zafiris Zafirelis

    President and CEO, HbO2 Therapeutics LLC

11:05 am - 11:30 am
Coffee Break – Aragon Pre-Function North

Visit Exhibits

Session 3 | Dried Plasma, Artificial RBCs and Pathogen Reduction of Blood

11:30 am - 11:45 am
Lyophilized Plasma and Plasma in Trauma Associated Sepsis
  • Rosemary Kozar MD, PhD

    Professor of Surgery
    Vice Chair of Research
    University of Maryland

11:45 am - 12:00 pm
Pathogen Reduction in Transfusion Safety of Novel Blood Products
  • Larry Corash MD

    Senior VP and Chief Scientific Officer Cerus Inc.

12:00 pm - 12:15 pm
Novel Bio-Inspired Artificial RBC (Erythromer): Early Pre-clinical Results
  • Allan Doctor MD

    Professor of Pediatrics, Biochemistry and Bioengineering
    Director, Center for Blood Oxygen Transport and Hemostasis
    University of Maryland School of Medicine

12:15 pm - 12:30 pm
Blood Banks Providing Novel and Alternative Blood Products
  • Beth Shaz MD

    President AABB
    Chief Medical and Scientific Officer
    Senior Vice President at New York Blood Center

12:30 pm - 12:45 pm
Question & Answer Panel | Session 3
12:45 pm - 1:45 pm
Lunch

Visit Exhibits

Session 4 | Novel Platelet and Platelet Derived Products

1:45 pm - 2:00 pm
Freeze Dried Platelets in Trauma Related Applications- Pre-clinical to Clinical Translation
  • Mike Fitzpatrick PhD

    COL, USA, Ret.
    President & Director of Research and Development, Cellphire Inc.

2:00 pm - 2:15 pm
Platelets and Platelet Dysfunction in Trauma
  • Karim Brohi MD

    Professor of Trauma Sciences
    Queen Mary University of London
    Director London Major Trauma System

2:15 pm - 2:30 pm
Cold Stored Platelets in Trauma – The Optimal Product for Military and Civilian Use
  • Andrew (Andre) Cap MD, PhD

    COL, USA
    Associate Professor of Medicine
    Uniformed Services University of the Health Sciences
    Chief, Blood Research Program
    US Army Institute for Surgical Research

2:30 pm - 2:45 pm
Platelet Biology and Cytoskeletal Mechanics
  • Owen McCarty PhD

    Professor and Chair of Department of Biomedical Engineering
    Professor of Department of Cell & Development Biology
    Oregon Health & Science University

2:45 pm - 3:00 pm
Regulating the Endotheliopathy of Trauma with 4C Platelets & Platelet Extracellular Vesicles
  • Shibani Pati MD, PhD

    CTTACC Conference Chair
    Professor of Laboratory Medicine, UCSF
    Scientific Director of Cellular Therapies

3:00 pm - 3:15 pm
Freeze Dried Platelets in Treating Traumatic Brain Injury
  • Alpa Mahuvakar Trivedi PhD

    Research Professor
    Department of Laboratory Medicine, UCSF

3:15 pm - 3:30 pm
Question & Answer Panel | Session 4
  • Moderator: Lucy Kornblith MD

    Assistant Professor of Surgery
    Trauma Surgery and Surgical Critical Care
    University of California San Francisco
    Zuckerberg San Francisco General Hospital

  • Moderator: Heather Pidcoke MD PhD

    Chief Medical Research Officer
    Associate Director, Research
    Translational Medicine Institute
    Colorado State University

3:30 pm - 4:00 pm
Coffee Break – Aragon Pre-Function North

Visit Exhibits

Session 5 | Product Development, Support and Regulatory Approval of Novel Blood Products

4:00 pm - 4:15 pm
Priorities for Military Medicine and Research
  • Michael Davis MD, FACS

    Col, USAF
    Director of the US Army Medical Research and Materiel Command’s Combat Casualty Care Research Program (CCCRP)

4:15 pm - 4:30 pm
Mission of BARDA in Novel Blood Product Development
  • Erika Davies PhD

    Health Scientist
    Division of Chemical, Biological, Radiological, and Nuclear Countermeasures (DBRN)
    Biomedical Advanced Research and Development Authority (BARDA)

4:30 pm - 5:30 pm
Introduction to Novel Product Development in Transfusion Medicine-Novel Blood Products

Discussion will focus upon the current successes, challenges and translational barriers that exist in the development of novel blood products. Including dried plasma, dried platelets, dried cryoprecipitate, and more.

  • Moderator: Kenneth Bertram MD, PhD

    Co-Chair CTTACC
    COL, USA, Ret.
    Professor of Regenerative Medicine
    Wakeforest University

  • Moderator: Richard Gonzales MS, MT(ASCP)SBB

    COL, USA, Ret.
    President and CEO
    Richblo2d Biologics Consulting Services LLC

  • Larry Corash MD

    Senior VP and Chief Scientific Officer Cerus Inc.

  • Mark Popovsky MD

    Chief Medical Officer
    Velico Medical, Inc

  • Mike Fitzpatrick PhD

    COL, USA, Ret.
    President & Director of Research and Development, Cellphire Inc.

  • Peter Marks MD, PhD

    Director of the Center for Biologics Evaluation and Research (CBER)
    Food and Drug Administration (FDA)

5:30 pm - 6:30 pm
Reception – Buena Vista Terrace
6:30 pm - 9:00 pm
Dinner – Promanade

Friday, December 13 | Cellular Therapies in Trauma and Critical Care Medicine

The goal of this session is to discuss and learn about the state of the science of cellular therapies in trauma and critical care. Pre-clinical and clinical studies will be presented in traumatic brain injury (TBI), Spinal Cord Injury (SCI), acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), cardiac disease, wound healing and tissue and bone regeneration.

7:00 am - 8:00 am
Breakfast – Aragon Lawn

Visit Exhibits

7:00 am - 1:00 pm
Registration Area Open – Aragon Pre-Function North

Badge and Materials Pickup

8:00 am - 8:30 am
Plenary Talk | A Success Story in Cellular Therapies: Allogeneic CAR-T Cell Therapy
  • David Chang MD, PhD

    CEO and President, Allogene Therapeutics Inc.

Session 1 | Cellular Therapies in Critical Care Medicine

8:30 am - 8:50 am
IPSC Derived Cardiomyocytes in Cardiac Disease and Repair
  • Joseph C. Wu MD, PhD

    Director, Stanford Cardiovascular Institute Simon H. Stertzer, MD
    Professor of Medicine & Radiology Stanford University School of Medicine

8:50 am - 9:10 am
Innate Immunity in Injury
  • Clifford Lowell MD, PhD

    Professor and Distinguished Chairman Department of Laboratory Medicine, UCSF

9:10 am - 9:30 am
Cellular Therapies in ARDS – Pre-clinial to Clinical Trials
  • Michael Matthay MD

    Professor of Pulmonary Critical Care Medicine
    Associate Director of ICU
    University of California San Francisco

9:30 am - 9:50 am
Multipotent Adult Progenitor Cells in ARDS
  • Robert Mays PhD

    Vice President, Regenerative Medicine
    Head of Neurosciences, Athersys, Inc.

9:50 am - 10:05 am
Question & Answer Panel | Session 1
  • Moderator: Charles Cox MD

    Professor of Pediatric Surgery
    Children’s Fund Distinguished Professor
    Center for Stem Cell & Regenerative Medicine
    University of Texas Houston

10:05 am - 10:25 am
Coffee Break – Aragon Pre-Function North

Visit Exhibits

Session 2 | Cellular Therapies in Neurotrauma and Organ Regeneration

10:25 am - 10:45 am
Adult and Pediatric Clinical Trials of HSCs and MAPCs in Traumatic Brain Injury (TBI)
  • Charles Cox MD

    Professor of Pediatric Surgery
    Children’s Fund Distinguished Professor
    Center for Stem Cell & Regenerative Medicine
    University of Texas Houston

10:45 am - 11:05 am
Human Stem Cell Grafts in Spinal Cord Injury (SCI) and Repair
  • Ephron Rosenzweig PhD

    Assistant Professor of Neurosciences
    Center for Neural Repair
    University of California San Diego

11:05 am - 11:25 am
Human Clinical Trial of Neural Progenitor Cells in SCI
  • Joseph Ciacci MD

    Professor of Neurosurgery
    Vice Chair of Research
    University of California San Diego

11:25 am - 11:45 am
Organ Regeneration in Trauma
  • Anthony Atala MD

    Professor of Surgery
    Chair, Department of Urology
    Director, Wake Forest Institute for Regenerative Medicine at Wake Forest University

11:45 am - 12:00 pm
Question & Answer Panel | Session 2
12:00 pm - 1:00 pm
Lunch – Aragon Lawn

Visit Exhibits

Session 3 | Cellular Therapies for Wound Healing, Bone Healing and Burns

1:00 pm - 1:20 pm
Cellular Therapies in Wound Healing and Tissue Injury
  • Jan Nolta PhD

    Professor and Stem Cell Program Director
    UC Davis Medical Center
    Editor of the Journal – Stem Cells

1:20 pm - 1:40 pm
Bone Healing and Blood Production with Stem Cells
  • Joy Wu MD

    Assistant Professor of Medicine
    Co Director Translational Investigator Program
    Stanford University

1:40 pm - 2:00 pm
French Military Clinical Experience with MSCs in Thermal and Radiation Burn Injury
  • Christophe Martinaud MD

    Professor of Transfusion Medicine and Cell Therapy
    French Military Blood Institute Clamart

2:00 pm - 2:10 pm
Question & Answer Panel | Session 3

Session 4 | New Technologies, Regulatory Issues and Challenges in the Field

2:10 pm - 2:30 pm
Platelet Biogenesis & IPSC-derived Platelets
  • Jonathan Thon PhD

    CEO & Co-Founder at Platelet BioGenesis

2:30 pm - 2:50 pm
The Cell Therapy Translational Pipeline from Bench to Bedside with New Emerging Technologies: Perspectives on CAR-T cells and IPSC derived Cells and Tissue
  • Jürgen Schmitz PhD

    Chief Scientific Officer
    Miltenyi Biotec

2:50 pm - 3:10 pm
FDA Perspective: Cellular Therapies
  • Peter Marks MD, PhD

    Director of the Center for Biologics Evaluation and Research (CBER)
    Food and Drug Administration (FDA)

3:10 pm - 3:30 pm
Session 4 Question & Answer Panel | Concluding Remarks

Presented by the University of California San Francisco Department of Laboratory Medicine

SIGNUP FOR MORE INFORMATION

Questions? Email us at info@cttacc.org or call 303-238-0685